Cellular pharmacology

Departments of Neurology and Molecular and Cellular Pharmacology, University of Miami, Miller School of Medicine, Miami, Florida... 

Ronghe, M., Burke, G.A., Lowis, S.R, and Estlin, E.J. 2001. Remission induction therapy for childhood acute lymphoblastic leukaemia clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines. Cancer Treatment Reviews 27(6), 327-337. 

Data from Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. 2006, http/AMM/vAIDSinfo.NIH.gov Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nudeotide-andogue reverse-transcriptase inhibitors and its relationship to dinical toxdties. din Infect Dis 2004 38 743-753 and produd information for agents... 

Horber DH, Schott CH, Schwendener RA. Cellular pharmacology of a liposomal preparation of ISf-hexadecyl-l-P-D-arabinofuranosylcytosine, a lipophilic derivative of 1-P-D-arabinofuranosylcytosine. Br J Cancer 1995 71 957. 

Horber DH, Schott H, Schwendener RA. Cellular pharmacology of N" -hexade-cyl-l-P-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 1995 36 483. 

The cause of the cell cycle specificity of the bisindole alkaloids may be associated with the ability of these compounds to interact with the protein tubulin and thereby inhibit the polymerization (and depolymerization) of microtubules (16,17). In this respect the cellular pharmacology of vinca alkaloids is similar to that of other cytotoxic natural products such as colchicine or podophyllotoxin. On closer inspection, however, Wilson determined that the specific binding site on tubulin occupied by vinblastine or vincristine is chemically distinct from the site occupied by the other natural products (18). Subsequent experiments have determined that the maytansinoids, a class of ansa-macrocycles structurally distinct from the bisindoles, may bind to tubulin at an adjacent (or overlapping) site (19). A partial correlation of the antimitotic activity of these compounds with their tubulin binding properties has been made, but discrepancies in cellular uptake probably preclude any quantitative relationship of these effects (20). 

The functionality associated with N-1 of the vindoline portion of the bisindole alkaloids confers much biological diversity to these compounds. This property is exemplified by the differences in the cellular pharmacology, antitumor efficacy, and toxicity of vinblastine (1) and vincristine (2). Since 1 is isolated from extracts of Catharanthus in approximately 10-fold greater yield, it is not surprising that several oxidative methods have... 

Beck has contributed an incisive review of investigations from his laboratory and those of other scientists on the cellular pharmacological aspects of resistance to vinblastine and related compounds (76). Important cellular characteristics that are frequently associated with resistance to vinblastine include cross-resistance, not only to closely related compounds such as vincristine and vindesine but also to other basic naturally occurring compounds. Concomitant resistance to vinblastine and representative anthracyclines (e.g., doxorubicin) may involve reduced abilities... 

Andrews PA, Howell SB. Cellular pharmacology of cisplatin perspective on mechanisms of acquired resistance. Cancer Cells 1990 2 35 43. 

Abbruzzese JL, Grunewald R, Weeks EA, et al. A Phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991 9 491 -98. 

Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am JPediatr Hematol Oncol 1993 15 80-86. 

Baurain, R., M. Masquelier, D. Deprez-De Campeneere, and A. Trouet. 1980. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemia cells in vitro andin vivo. J. Med. Chem23 1171-1174. 

Zenebergh, A., Baurain, R., and Trouet, A. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells. Eur. J. Cancer Clin. Oncol. 20(1) 115-121, 1984. 

Nilsson S et al (2005) Oestrogen receptors and selective oestrogen receptor modulators molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 96 15-25... 

Gottesman MM, Pastan I. Modulation of the Multidrug Resistance Phenotype. Cellular Pharmacology 1993 1 (suppl 1) S 11 I S 112. 

Wang Y, He QY, Sun RW, Che CM, Chiu JF (2007) Cellular pharmacological properties of gold(III) porphyrin la, a potential anticancer drug lead. Eur J Pharmacol 554 113-122... 

For all of these analogues, it may be expected that varying characteristics of cellular uptake, interaction with cytoplasmic nucleophiles, DNA-ad-duct formation, DNA topologic alterations, and interaction with DNA-re-pair systems will determine their cellular pharmacology. Understanding... 

Differences in toxicity and in specificity for particular tumor types are influenced by the cellular pharmacology and by the pharmacokinetic char-... 

The discovery of a second cyclooxygenase enzyme initiated an explosion of research. This research showed that COX-2 was distinguished from COX-1 by a slightly larger molecular mass, rarity of mRNA expression, and induction by growth factors and cytokines (280). Further work has yielded information with significant detail in the biochemical, cellular, pharmacological, and structural differences between the two enzymes. 

Baurain R, Masquelier M, Deprezedcampeneere D, et al. Amino acid and dipeptide derivatives of daunorubicin. 2. cellular pharmacology and anti-tumor activity on L1210 leukemic-cells in vitro and in vivo. J Med Chem 1980 23 1171-1174. 

Plunkett W, lacoboni S, Keating MJ. Cellular pharmacology and optimal therapy concentrations of l-/i-D-arabinofuranosylcytosine 51-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose l-/i-D-arabinofuranosylcytosine. Scand J Haematol 1986 44 51-59. 

Rippley, R.K., R.C. Wilson, and C.L. Stokes, Effect of cellular pharmacology on drug distribution in tissues. Biophysical Journal, 1995, 69, 825-839. 

S. Rockwell, A.C. Sartorelli, M. Tomasz and K.A. Kennedy, Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Revs., 12 (1993) 165. 

---